Cargando…
Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials
BACKGROUND: Cystic fibrosis (CF) is a life-threatening genetic disease, affecting around 10 500 people in the UK. Precision medicines have been developed to treat specific CF-gene mutations. The newest, elexacaftor/tezacaftor/ivacaftor (ELEX/TEZ/IVA), has been found to be highly effective in randomi...
Autores principales: | Keogh, Ruth H, Cosgriff, Rebecca, Andrinopoulou, Eleni-Rosalina, Brownlee, Keith G, Carr, Siobhán B, Diaz-Ordaz, Karla, Granger, Emily, Jewell, Nicholas P, Lewin, Alex, Leyrat, Clemence, Schlüter, Daniela K, van Smeden, Maarten, Szczesniak, Rhonda D, Connett, Gary J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940731/ https://www.ncbi.nlm.nih.gov/pubmed/34556554 http://dx.doi.org/10.1136/thoraxjnl-2020-216265 |
Ejemplares similares
-
Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data
por: Schlüter, Daniela K, et al.
Publicado: (2022) -
Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
por: Granger, Emily, et al.
Publicado: (2023) -
Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies
por: Bresnick, Kathryn, et al.
Publicado: (2021) -
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018) -
Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database
por: Mehta, Zumi, et al.
Publicado: (2021)